Deep Track Capital, LP
GREENWICH, CT · CIK 1856083 · 13F filing filed 2024-08-14
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Others nearbyGreenwich, CT
Options: 1 call positions ($1.8m notional), 0 put positions (— notional) – listed below, not included above.
Holdings, Q2 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| AMGEN INC AMGN | $179.7m5.37% | Added +25.0k |
| ARGENX SE ARGX | $172.0m5.14% | Added +100.0k |
| AXSOME THERAPEUTICS INC AXSM | $149.1m4.45% | Added +548.1k |
| DYNE THERAPEUTICS INC DYN | $141.2m4.22% | Reduced -555.4k |
| SPRINGWORKS THERAPEUTICS INC SWTX | $139.4m4.16% | Added +220.1k |
| INSMED INC INSM | $134.0m4.00% | Reduced -2.8m |
| GUARDANT HEALTH INC GH | $130.0m3.88% | Reduced -1.5m |
| DYNAVAX TECHNOLOGIES CORP DVAX | $122.4m3.66% | Added +1.8m |
| ALNYLAM PHARMACEUTICALS INC ALNY | $121.5m3.63% | Reduced -332.3k |
| INTELLIA THERAPEUTICS INC NTLA | $107.4m3.21% | Added +589.2k |
| INTRA-CELLULAR THERAPIES INC ITCI | $105.3m3.15% | Added +37.9k |
| APELLIS PHARMACEUTICALS INC APLS | $95.9m2.86% | Added +1.5m |
| IONIS PHARMACEUTICALS INC IONS | $95.3m2.85% | Added +626.5k |
| OCULAR THERAPEUTIX INC OCUL | $87.0m2.60% | Unchanged |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $85.2m2.55% | Added +1.0m |
| ALKERMES PLC ALKS | $84.3m2.52% | Unchanged |
| NURIX THERAPEUTICS INC NRIX | $83.3m2.49% | Added +993.7k |
| IMMUNOVANT INC IMVT | $76.1m2.27% | Added +2.4m |
| BICYCLE THERAPEUTICS PLC BCYC | $70.6m2.11% | Unchanged |
| PLIANT THERAPEUTICS INC PLRX | $64.2m1.92% | Added +222.3k |
| TRAVERE THERAPEUTICS INC TVTX | $60.6m1.81% | Unchanged |
| VERONA PHARMA PLC VRNA | $57.8m1.73% | Added +812.6k |
| ABIVAX SA ABVX | $55.3m1.65% | Reduced -117.7k |
| GERON CORP GERN | $55.1m1.65% | Reduced -17.5m |
| AUTOLUS THERAPEUTICS PLC AUTL | $53.1m1.59% | Unchanged |
| TG THERAPEUTICS INC TGTX | $51.1m1.52% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $51.0m1.52% | Added +467.8k |
| KYMERA THERAPEUTICS INC KYMR | $44.8m1.34% | Added +237.8k |
| MIND MEDICINE MINDMED INC COM NEW | $44.0m1.31% | Reduced -562.9k |
| OLEMA PHARMACEUTICALS INC OLMA | $43.3m1.29% | Added +774.6k |
| TERNS PHARMACEUTICALS INC COM | $41.5m1.24% | Unchanged |
| SPYRE THERAPEUTICS INC SYRE | $41.3m1.23% | Added +543.2k |
| APOGEE THERAPEUTICS INC COM | $39.4m1.18% | Reduced -1.3m |
| STRUCTURE THERAPEUTICS INC GPCR | $37.3m1.11% | Added +909.9k |
| ANI PHARMACEUTICALS INC ANIP | $29.7m0.89% | Reduced -355.9k |
| EDITAS MEDICINE INC EDIT | $28.0m0.84% | Added +472.7k |
| CLIMB BIO INC CLYM | $27.8m0.83% | New |
| HILLEVAX INC COM | $26.5m0.79% | Reduced -739.8k |
| KORRO BIO INC KRRO | $26.1m0.78% | New |
| SILENCE THERAPEUTICS PLC SLN | $25.8m0.77% | Reduced -284.1k |
| NEKTAR THERAPEUTICS COM | $22.2m0.66% | Reduced -524.5k |
| ENGENE HOLDINGS INC COM | $21.2m0.63% | Unchanged |
| ALECTOR INC ALEC | $21.0m0.63% | Added +862.6k |
| 89BIO INC ETNB | $18.4m0.55% | New |
| FATE THERAPEUTICS INC FATE | $18.3m0.55% | Unchanged |
| INOVIO PHARMACEUTICALS INC INO | $16.7m0.50% | New |
| PRAXIS PRECISION MEDICINES I PRAX | $16.1m0.48% | New |
| CYBIN INC COM | $15.8m0.47% | Unchanged |
| CONTEXT THERAPEUTICS INC CNTX | $14.9m0.44% | New |
| PYXIS ONCOLOGY INC PYXS | $13.8m0.41% | Unchanged |
| INVIVYD INC IVVD | $12.0m0.36% | Unchanged |
| ZURA BIO LTD ZURA | $11.5m0.34% | Added +760.8k |
| KURA ONCOLOGY INC KURA | $7.9m0.24% | New |
| CYTOKINETICS INC CYTK | $7.2m0.21% | New |
| REGULUS THERAPEUTICS INC RGLS | $5.8m0.17% | Reduced -4.0k |
| ALTO NEUROSCIENCE INC ANRO | $5.5m0.16% | Reduced -88.3k |
| AGENUS INC AGEN | $5.2m0.16% | New |
| ALLAKOS INC ALLKG | $5.0m0.15% | Unchanged |
| SYROS PHARMACEUTICALS INC SYRS | $4.3m0.13% | Unchanged |
| RELMADA THERAPEUTICS INC RLMD | $3.7m0.11% | Reduced -5.3k |
| EDGEWISE THERAPEUTICS INC EWTX | $3.4m0.10% | New |
| SCHOLAR ROCK HLDG CORP SRRK | $3.1m0.09% | Reduced -307.4k |
| REPARE THERAPEUTICS INC RPTX | $3.0m0.09% | Reduced -1.8m |
| COGENT BIOSCIENCES INC COGT | $2.6m0.08% | Reduced -7.8k |
| VIGIL NEUROSCIENCE INC VIGL | $2.4m0.07% | Reduced -997.7k |
| ALIGOS THERAPEUTICS INC COM | $2.1m0.06% | Unchanged |
| METAGENOMI INC MGX | $1.9m0.06% | Unchanged |
Sold out since Q1 2024
| Security | Value then |
|---|---|
| TOURMALINE BIO INC TRML | $36.5m1.6m shares |
| PACIFIC BIOSCIENCES CALIF IN PACB | $26.2m7.0m shares |
| NUVALENT INC | $20.6m274.5k shares |
| AGENUS INC | $18.4m31.7m shares |
| NEUMORA THERAPEUTICS INC. NMRA | $13.8m1.0m shares |
| ANAPTYSBIO INC ANAB | $11.9m529.5k shares |
| ULTRAGENYX PHARMACEUTICAL IN RARE | $7.8m167.8k shares |
| MERSANA THERAPEUTICS INC | $2.6m579.7k shares |
| PRIME MEDICINE INC PRME | $2.1m303.7k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| NEUMORA THERAPEUTICS INC. NMRA · Call | $1.8m180.5k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 27.
| Company | Stake |
|---|---|
| LB PHARMACEUTICALS INC LBRX · 13D · filed 2026-02-10 | 11.7%≈ $108.8m |
| ALTIMMUNE INC ALT · 13G · filed 2026-04-30 | 10.0%≈ $59.0m |
| PROMIS NEUROSCIENCES INC PMN · 13G · filed 2026-02-06 | 10.0%≈ $11.9m |
| VERASTEM INC VSTM · 13G · filed 2025-11-21 | 10.0%≈ $29.5m |
| COMPASS PATHWAYS PLC CMPS · 13G · filed 2025-01-17 | 10.0% |
| RAPT THERAPEUTICS INC 13G · filed 2024-12-23 | 9.9% |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX · 13G · filed 2026-08-14 | 9.7%≈ $155.7m |
| OCULAR THERAPEUTIX INC OCUL · 13G · filed 2026-05-15 | 9.5%≈ $204.7m |
| MAZE THERAPEUTICS INC MAZE · 13G · filed 2025-08-14 | 9.0%≈ $117.8m |
| IMMUNIC INC 13G · filed 2026-03-04 | 8.7% |
| ALECTOR INC ALEC · 13G · filed 2026-10-23 | 8.6%≈ $21.3m |
| TARSUS PHARMACEUTICALS INC TARS · 13G · filed 2026-05-15 | 8.5%≈ $226.6m |
| X4 PHARMACEUTICALS INC XFOR · 13G · filed 2026-08-14 | 8.3%≈ $37.6m |
| CONTEXT THERAPEUTICS INC CNTX · 13G · filed 2025-05-15 | 8.3%≈ $4.1m |
| HEMAB THERAPEUTICS HLDGS INC COAG · 13G · filed 2026-05-08 | 8.2%≈ $132.3m |
| CORMEDIX INC CRMD · 13G · filed 2026-05-15 | 7.9%≈ $49.3m |
| NURIX THERAPEUTICS INC NRIX · 13G · filed 2026-08-14 | 7.5%≈ $187.7m |
| CENTURY THERAPEUTICS INC IPSC · 13G · filed 2026-01-15 | 7.3%≈ $33.0m |
| ACLARIS THERAPEUTICS INC ACRS · 13G · filed 2026-03-17 | 7.0%≈ $49.4m |
| AVALO THERAPEUTICS INC AVTX · 13G · filed 2026-08-14 | 6.9%≈ $66.7m |
| MIND MEDICINE MINDMED INC 13G · filed 2025-11-14 | 6.9% |
| ENGENE HOLDINGS INC 13G · filed 2025-11-18 | 6.7% |
| BICARA THERAPEUTICS INC BCAX · 13G · filed 2026-05-15 | 6.2%≈ $120.6m |
| ALUMIS INC ALMS · 13G · filed 2026-04-07 | 6.0%≈ $207.2m |
| STRUCTURE THERAPEUTICS INC GPCR · 13G · filed 2026-02-13 | 6.0% |
Trades reported as a company insider in Q2 2024
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2024-05-10 | NEKTAR THERAPEUTICS 10% owner · See Footnote | Sold | $99.7k56.0k shares |